Sangamo Therapeutics (SGMO) Expected to Announce Earnings on Monday

Sangamo Therapeutics (NASDAQ:SGMO) will likely be posting its quarterly earnings results before the market opens on Monday, March 17th. Analysts expect Sangamo Therapeutics to post earnings of ($0.09) per share and revenue of $11.70 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Sangamo Therapeutics Price Performance

Shares of SGMO stock opened at $0.98 on Friday. The firm has a 50-day moving average of $1.10 and a 200-day moving average of $1.40. The company has a market cap of $204.72 million, a P/E ratio of -1.31 and a beta of 1.49. Sangamo Therapeutics has a one year low of $0.30 and a one year high of $3.18.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Truist Financial lowered their target price on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. StockNews.com downgraded shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. Wells Fargo & Company lowered their target price on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a report on Tuesday, December 31st. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a report on Monday, January 27th. Finally, Jefferies Financial Group reduced their price target on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, December 31st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $5.80.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.